Market Overview:
The global fibrin degradation product (FnDP) assays market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of thrombotic disorders, rising demand for point-of-care testing, and technological advancements in FnDP assays. Based on type, the global fibrin degradation product (FnDP) assays market is segmented into plasma and serum. The serum segment is expected to account for the majority share of the global FnDP assays market in 2018. This can be attributed to factors such as rising demand for serological tests and growing awareness about serological tests among healthcare professionals and patients. Based on application, the global fndp assaymarket is segmented into hospital laboratories, specialty clinics, diagnostic laboratories, and others (academic research institutes and contract research organizations).
 Assays Industry Outlook.svg)
Product Definition:
A fibrin degradation product assay is a laboratory test used to measure the amount of a particular protein in the blood. This protein, called fibrin degradation product, is released when clots break down. Fibrin degradation product assays are used to help diagnose and monitor conditions that affect clotting ability, such as disseminated intravascular coagulation (DIC) and liver disease.
Plasma:
Plasma is the liquid part of blood. It is mostly known for its role in clotting. However, it also plays a vital role in disease diagnosis and research. In addition, there are various other functions of plasma such as protein synthesis, vitamin C & D production (if consumed), cell growth & development along with many others that are yet to be discovered or identified completely.
The growing usage of plasma in biomedical research.
Serum:
The global serum and its usage in fibrin degradation product (FnDP) assays market size was valued at USD 6.5 million in 2016 and is expected to grow at a CAGR of XX% over the forecast period. The increasing prevalence of cardiovascular diseases, growing demand for early diagnostic procedures, rising geriatric population base, and technological advancements are some major factors that are driving the growth of this industry globally.
Application Insights:
The hospital application segment accounted for the largest share of 60.0% in 2017. The rising prevalence of chronic diseases, such as cardiovascular, cancer, and diabetes mellitus is expected to drive the demand for fibrin degradation products in hospital applications over the forecast period. In addition, a growing number of hospitals coupled with increasing R&D investments by pharmaceutical companies are anticipated to propel market growth over the coming years.
Specialty clinics are anticipated to be one of fastest-growing segments owing to an increase in patient awareness regarding various health issues and changing lifestyles that have led to increased incidences of several chronic diseases including cancer and diabetes mellitus during past few decades. A rise in demand for advanced diagnostics methods that can identify genetic mutations responsible for causing these disorders is also expected fuel product demand from specialty clinics over next eight years or so.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of major players and well-established healthcare infrastructure. The region is expected to maintain its dominance over the forecast period due to increasing prevalence of thrombosis, cancer, & cardiovascular diseases coupled with rising investment by manufacturers in R&D for development of novel diagnostic products.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rapid economic development along with improving healthcare infrastructure and facilities in emerging countries such as China & India. Furthermore, growing medical tourism industry will also boost product demand during the projected time frame. In addition, increasing incidence of venous disorders due high consumption of tobacco smoking has led Asia Pacific into being one of leading producers & consumers across all regions globally.
FnDP assay market share by application (Hospital/ specialty clinics; diagnostic laboratories).
Growth Factors:
- Increasing incidence of cardiovascular diseases (CVDs) and cancer
- Growing demand for early diagnosis and treatment of CVDs and cancer
- Rising awareness about the benefits of FnDP assays
- Technological advancements in FnDP assay kits and instruments
- Growing number of clinical laboratories and research institutes
Scope Of The Report
Report Attributes
Report Details
Report Title
Fibrin Degradation Product (FnDP) Assays Market Research Report
By Type
Plasma, Serum
By Application
Hospital, Specialty Clinics, Diagnostic Laboratory, Others
By Companies
Sekisui Diagnostics (Sekisui Chemical), Randox Laboratories, Beckman Coulter Inc. (Danaher Corporation), Kamiya Biomedical Company, ADALTIS S.r.l., SDIX, LLC, Lab Mark A.s., Abbott Laboratories, IBL International (Tecan Group Ltd.), Analytik Jena AG
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
186
Number of Tables & Figures
131
Customization Available
Yes, the report can be customized as per your need.
Global Fibrin Degradation Product (FnDP) Assays Market Report Segments:
The global Fibrin Degradation Product (FnDP) Assays market is segmented on the basis of:
Types
Plasma, Serum
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Specialty Clinics, Diagnostic Laboratory, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sekisui Diagnostics (Sekisui Chemical)
- Randox Laboratories
- Beckman Coulter Inc. (Danaher Corporation)
- Kamiya Biomedical Company
- ADALTIS S.r.l.
- SDIX, LLC
- Lab Mark A.s.
- Abbott Laboratories
- IBL International (Tecan Group Ltd.)
- Analytik Jena AG
 Assays Market Overview.svg)
Highlights of The Fibrin Degradation Product (FnDP) Assays Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Plasma
- Serum
- By Application:
- Hospital
- Specialty Clinics
- Diagnostic Laboratory
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Fibrin Degradation Product (FnDP) Assays Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Assays Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Fibrin degradation product assays (FnDPAs) are a type of assay used to measure the level of fibrin degradation products in a sample. FnDPAs can be used to determine the extent of fibrinolysis in a sample, and can also be used to monitor the effectiveness of treatments that aim to reduce or stop fibrinolysis.
Some of the major players in the fibrin degradation product (fndp) assays market are Sekisui Diagnostics (Sekisui Chemical), Randox Laboratories, Beckman Coulter Inc. (Danaher Corporation), Kamiya Biomedical Company, ADALTIS S.r.l., SDIX, LLC, Lab Mark A.s., Abbott Laboratories, IBL International (Tecan Group Ltd.), Analytik Jena AG.
The fibrin degradation product (fndp) assays market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Fibrin Degradation Product (FnDP) Assays Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Fibrin Degradation Product (FnDP) Assays Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Fibrin Degradation Product (FnDP) Assays Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Fibrin Degradation Product (FnDP) Assays Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Fibrin Degradation Product (FnDP) Assays Market Size & Forecast, 2018-2028
4.5.1 Fibrin Degradation Product (FnDP) Assays Market Size and Y-o-Y Growth
4.5.2 Fibrin Degradation Product (FnDP) Assays Market Absolute $ Opportunity
Chapter 5 Global Fibrin Degradation Product (FnDP) Assays Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Type
5.2.1 Plasma
5.2.2 Serum
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Fibrin Degradation Product (FnDP) Assays Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Specialty Clinics
6.2.3 Diagnostic Laboratory
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Fibrin Degradation Product (FnDP) Assays Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Fibrin Degradation Product (FnDP) Assays Analysis and Forecast
9.1 Introduction
9.2 North America Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Type
9.6.1 Plasma
9.6.2 Serum
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Specialty Clinics
9.10.3 Diagnostic Laboratory
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Fibrin Degradation Product (FnDP) Assays Analysis and Forecast
10.1 Introduction
10.2 Europe Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Type
10.6.1 Plasma
10.6.2 Serum
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Specialty Clinics
10.10.3 Diagnostic Laboratory
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Fibrin Degradation Product (FnDP) Assays Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Type
11.6.1 Plasma
11.6.2 Serum
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Specialty Clinics
11.10.3 Diagnostic Laboratory
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Fibrin Degradation Product (FnDP) Assays Analysis and Forecast
12.1 Introduction
12.2 Latin America Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Type
12.6.1 Plasma
12.6.2 Serum
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Specialty Clinics
12.10.3 Diagnostic Laboratory
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Fibrin Degradation Product (FnDP) Assays Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Type
13.6.1 Plasma
13.6.2 Serum
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Fibrin Degradation Product (FnDP) Assays Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Specialty Clinics
13.10.3 Diagnostic Laboratory
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Fibrin Degradation Product (FnDP) Assays Market: Competitive Dashboard
14.2 Global Fibrin Degradation Product (FnDP) Assays Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sekisui Diagnostics (Sekisui Chemical)
14.3.2 Randox Laboratories
14.3.3 Beckman Coulter Inc. (Danaher Corporation)
14.3.4 Kamiya Biomedical Company
14.3.5 ADALTIS S.r.l.
14.3.6 SDIX, LLC
14.3.7 Lab Mark A.s.
14.3.8 Abbott Laboratories
14.3.9 IBL International (Tecan Group Ltd.)
14.3.10 Analytik Jena AG
